☆ 4.8 Article

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

SCIENCE (2021)

Related references

Note: Only part of the references are listed.

Letter Immunology

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Pragya D. Yadav et al.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Meng Yuan et al.

Summary: Since the outbreak of COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have collaborated to study the novel pandemic virus SARS-CoV-2. The focus has been on the antibody response to SARS-CoV-2, crucial for vaccine and therapeutic development. Most of the neutralizing antibodies for SARS-CoV-2 target the spike protein receptor binding domain (RBD).

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

Add to Collection

Article Cell Biology

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

Hangping Yao et al.

Summary: This study developed a therapeutic antibody cocktail against SARS-CoV-2 by exploiting antibody cooperativity, consisting of two antibodies that achieved synergistic neutralization through S1 shielding and conformational locking, blocking receptor attachment and viral membrane fusion to combat viral mutation escape. Additionally, a hypothetical third antibody partner was identified for further reinforcement as pan-SARS-CoVs therapeutics.

CELL RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Jiwan Ge et al.

Summary: The authors compare the crystal structures and investigate the neutralization mechanisms of three neutralizing antibodies against SARS-CoV-2 and find that one antibody, P2C-1F11, closely mimics binding of receptor ACE2 and displays the most potent neutralizing activity in vitro, as well as conferring protection against SARS-CoV-2 infection in Ad5-hACE2-sensitized mice.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Yunjiao Zhou et al.

Summary: This study found that neutralizing and ADE abilities of human SARS-CoV-2 antibodies are correlated with non-overlapping RBD epitopes they target.

CELL REPORTS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Wanwisa Dejnirattisai et al.

Summary: Antibodies play a crucial role in immune protection against SARS-CoV-2, with some being used as therapeutics. A study identified 377 human monoclonal antibodies, focusing on 80 that bind the virus spike, and found that most highly inhibitory antibodies can block the virus-receptor interaction. Novel binding modes of potent inhibitory antibodies were discovered, showing potential for prophylactic or therapeutic use in animal models.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Add to Collection

Editorial Material Immunology

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Jie Hu et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Microbiology

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors

Michael Mor et al.

Summary: Severe COVID-19 is associated with unique BCR signatures and multi-clonal neutralizing responses that are relatively frequent in the population. Combination antibody therapy can be effective in preventing and treating COVID-19.

PLOS PATHOGENS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Sarah A. Clark et al.

Summary: The study reveals that mutations occurring during the evolution of SARS-CoV-2 virus may lead to resistance against antibodies, posing challenges to long-term efficacy.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody evasion by the P.1 strain of SARS-CoV-2

Wanwisa Dejnirattisai et al.

Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.

CELL (2021)

Add to Collection

Article Microbiology

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara et al.

Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Hejun Liu et al.

Summary: This study presents a cross-neutralizing antibody, CV38-142, which can accommodate antigenic variation in SARS-related viruses, providing valuable information for addressing current and future antigenic drift in SARS-CoV-2 and protecting against zoonotic SARS-related coronaviruses.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Pengfei Wang et al.

Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.

CELL HOST & MICROBE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Sandile Cele et al.

Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class

Micah Rapp et al.

Summary: Antibodies derived from the VH1-2 gene have been shown to be potent neutralizing antibodies against SARS-CoV-2, with three VH1-2-derived antibodies (2-15, 2-43, and H4) using VH1-2-encoded motifs to recognize the receptor-binding domain (RBD) of the virus spike protein. Despite genetic similarities, these antibodies are able to recognize both up and down conformations of the RBD, with some antibodies using elongated CDRH3s to interact with glycan N343 on a neighboring RBD. The VH1-2 antibody class utilizes modular genetic elements for modular recognition, with VH gene specifying RBD recognition and CDRH3 specifying quaternary interactions.

CELL REPORTS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

Xing Zhu et al.

Summary: The UK variant of SARS-CoV-2 with the N501Y mutation shows increased infectivity due to tighter binding with the ACE2 receptor, but without significant structural changes. Important neutralization epitopes in the spike receptor binding domain are retained.

PLOS BIOLOGY (2021)

Add to Collection

Article Immunology

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

Xiaojian Han et al.

Summary: This study developed an effective screening method that enabled the generation of NAbs specific to SARS-CoV-2 with high neutralizing activity within 15 days. These NAbs exhibited advanced neutralizing potency and high affinity against SARS-CoV-2.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Dapeng Li et al.

Summary: Research has shown that some SARS-CoV-2 neutralizing antibodies can enhance virus infection in vitro, but in monkeys and mice, these antibodies can still protect against SARS-CoV-2. However, out of 46 monkeys infused with enhancing antibodies, three showed higher lung inflammation scores compared to controls.

CELL (2021)

Add to Collection

Article Immunology

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Ruoke Wang et al.

Summary: Research shows that the South African B.1.351 variant exhibits the highest resistance to current monoclonal antibodies and convalescent plasma from COVID-19-infected individuals, and the molecular basis for this resistance and potential antibody escape has been identified.

IMMUNITY (2021)

Add to Collection

Article Microbiology

Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants

Veronika Tchesnokova et al.

Summary: A recent global expansion of various independent SARS-CoV-2 variants with mutation L452R in the spike protein's receptor-binding domain has been reported. The emergence of these variants, including epsilon, delta, kappa, iota, and lambda, has been associated with increased viral transmissibility, infectivity, and pathogenicity due to the L452R mutation near the ACE2 interaction interface.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Tyler N. Starr et al.

Summary: An ideal therapeutic anti-SARS-CoV-2 antibody should have resistance to viral escape, activity against diverse sarbecoviruses, and provide high protection through viral neutralization and effector functions. Studies have found a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding in SARS-CoV-2 antibodies targeting the RBD, but identified some antibodies with exceptional sarbecovirus breadth and resistance to SARS-CoV-2 escape.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Lingshu Wang et al.

Summary: The study identified four receptor binding domain-targeting antibodies with potent neutralizing activity against 23 variants, including two ultrapotent antibodies. Combinations of these antibodies reduced the in vitro generation of escape mutants, showing potential in mitigating resistance development.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Gabriele Cerutti et al.

Summary: Emerging SARS-CoV-2 variants pose clinical concerns due to reduced neutralization by certain antibodies, but antibodies targeting specific regions may still be effective in bypassing mutations and providing potential therapeutic benefits.

STRUCTURE (2021)

Add to Collection

Article Immunology

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses

Georgia Bullen et al.

Summary: Passive immunization using monoclonal antibodies is crucial in the fight against COVID-19, and deep-mining the antibody repertoires of hospitalized patients has led to the discovery of a panel of potent neutralizing antibodies that can bind distinct viral epitopes, including those conserved in SARS-CoV-1. Analysis also revealed a novel binding epitope that is unlikely to be affected by mutations in major viral variants such as B.1.1.7, B.1.351, and B.1.1.28. Additionally, a highly convergent early antibody response was observed among patients, indicating potential for broader application in the fight against the virus.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Cell Biology

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

Andrea R. Shiakolas et al.

Summary: Research identifies antibodies from a recovered SARS-CoV donor sample that cross-react with the spike proteins of highly pathogenic SARS-CoV and SARS-CoV-2, as well as other coronaviruses. These antibodies mediate phagocytosis in vitro and reduce hemorrhagic pathology in murine lungs in vivo.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Meng Yuan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Stephen M. Kissler et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Tyler N. Starr et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Christoph Kreer et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

Add to Collection

Article Immunology

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Emilie Seydoux et al.

IMMUNITY (2020)

Add to Collection

Article Biochemical Research Methods

CoV-AbDab: the Coronavirus Antibody Database

Matthew I J Raybould et al.

BIOINFORMATICS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Jakob Kreye et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Shuo Du et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost et al.

NATURE MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis of a shared antibody response to SARS-CoV-2

Meng Yuan et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Jinkai Wan et al.

CELL REPORTS (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

M. Alejandra Tortorici et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Tal Noy-Porat et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Cell Biology

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

Nicholas C. Wu et al.

CELL REPORTS (2020)

Add to Collection

Article Immunology

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Hejun Liu et al.

IMMUNITY (2020)

Add to Collection

Letter Medicine, General & Internal

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Bina Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Nicholas K. Hurlburt et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Chemistry, Physical

Repertoire Builder: high-throughput structural modeling of B and T cell receptors

Dimitri Schritt et al.

MOLECULAR SYSTEMS DESIGN & ENGINEERING (2019)

Add to Collection

Article Biology

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Jasenko Zivanov et al.

ELIFE (2018)

Add to Collection

Editorial Material Infectious Diseases

GISAID: Global initiative on sharing all influenza data - from vision to reality

Yuelong Shu et al.

EUROSURVEILLANCE (2017)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Jesper Pallesen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Multidisciplinary Sciences

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

Damian C. Ekiert et al.

SCIENCE (2011)

Add to Collection

Article Biochemical Research Methods

Features and development of Coot

P. Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)

Add to Collection

Article Biochemical Research Methods

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Paul D. Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Add to Collection

Article Immunology

Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements

Scott D. Boyd et al.

JOURNAL OF IMMUNOLOGY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Appion: An integrated, database-driven pipeline to facilitate EM image processing

Gabriel C. Lander et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Add to Collection

Article Biochemistry & Molecular Biology

DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy

N. R. Voss et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Add to Collection

Review Microbiology

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus

Gunilla B. Karlsson Hedestam et al.

NATURE REVIEWS MICROBIOLOGY (2008)

Add to Collection

Review Biochemistry & Molecular Biology

Inference of macromolecular assemblies from crystalline state

Evgeny Krissinel et al.

JOURNAL OF MOLECULAR BIOLOGY (2007)

Add to Collection

Article Chemistry, Multidisciplinary

Phaser crystallographic software

Airlie J. McCoy et al.

JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)

Add to Collection

Article Biochemistry & Molecular Biology

Automated molecular microscopy: The new Leginon system

C Suloway et al.

JOURNAL OF STRUCTURAL BIOLOGY (2005)

Add to Collection

Article Chemistry, Multidisciplinary

UCSF chimera - A visualization system for exploratory research and analysis

EF Pettersen et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.